CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Liver NK cell inoculationbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01147380
NCT01147380Phase 1Completed
CompareCT.gov

A Novel Immunotherapy for Liver Transplant Patients With Hepatocellular Carcinoma: Anti-tumor Effect of IL2-activated Donor Liver Natural Killer Cell

Seigo Nishida·interventional·Posted Jun 22, 2010·Updated Mar 10, 2016

In Brief

A Phase 1 clinical trial evaluating Liver NK cell inoculation for Liver Cirrhosis and 2 related conditions. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate feasibility and safety of the adoptive transfer of activated natural killer (NK) cells extracted from cadaveric donor liver graft perfusate for liver transplant recipients with hepatocellular carcinoma (HCC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis, Hepatocellular Carcinoma, Evidence of Liver Transplantation
CountriesUnited States
CollaboratorsFlorida Department of Health

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 22, 2010
Enrollment StartJun 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 16.0 years ago

Interventions

Liver NK cell inoculationbiological

Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.